RRM1抗体;RRM1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using RRM1 mouse mAb against Hela (1), Jurkat (2), and A431 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using RRM1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using RRM1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using RRM1 mouse mAb with DAB staining.    

  
  

The RRM1 antibody is a crucial tool for studying the ribonucleotide reductase catalytic subunit M1 (RRM1), a key enzyme in DNA synthesis and repair. Ribonucleotide reductase (RNR) catalyzes the conversion of ribonucleotides to deoxyribonucleotides, essential for DNA replication and cell proliferation. The RNR holoenzyme consists of two subunits: RRM1. which harbors the catalytic site and allosteric regulatory sites, and RRM2 (or p53R2 in stress conditions), which provides a stable radical for catalysis. RRM1 expression is tightly regulated during the cell cycle and is often elevated in rapidly dividing cells, including cancer cells.

RRM1 antibodies are widely used in biomedical research to detect RRM1 protein levels in tissues or cell lines via techniques like Western blot, immunohistochemistry, or immunofluorescence. These antibodies help investigate RRM1's role in cancer progression, chemoresistance (e.g., resistance to gemcitabine in pancreatic or lung cancer), and its potential as a prognostic biomarker. Overexpression of RRM1 has been linked to poor survival in cancers such as non-small cell lung cancer (NSCLC), while low RRM1 levels may predict better response to antimetabolite therapies. Researchers also utilize RRM1 antibodies to explore its interplay with oncogenic signaling pathways and therapeutic targeting strategies. Validation of antibody specificity remains critical, as cross-reactivity with homologous proteins can affect data interpretation.